CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours

British Journal of Cancer

Volumn 87, Issue 12, 2002, Pages 1445-1448

  Sodha, Nayanta ^a   Bullock, S ^b   Taylor, R ^c   Mitchell, G ^a,b   Guertl Lackner, B ^b   Williams, R D ^b   Bevan, S ^b   Bishop, K ^a   McGuire, S ^b   Houlston, R S ^b   Eeles, R A ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; CHEK2; Mutation

Indexed keywords

ARGININE; CHECKPOINT KINASE 2; HISTIDINE; M PROTEIN; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR; WILD TYPE;

ADULT; ALLELES; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; PEDIGREE; POLYMERASE CHAIN REACTION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS;

EID: 0037011665     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600637     Document Type: Article

References (15)

1. Ahn J, Schwarz JK, Piwinca-Worms H, Canman CE (2000) Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res 60: 5934-5936
2. Ahn J, Li X, Davis HL, Canman CE (2002) Phosphorylation of Threonine 68 promotes oligomerization and autophosphorylation of the Chk2 protein kinase via the Forkhead-Associated (FHA) domain. J Biol Chem 277: 19389-19395
3. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R (2001) Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 85: 209-212
4. Antoniou AC, Pharoah PDP, McMullan G, Day NE, Ponder BAJ, Easton DF (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population based study. Genet Epidemiol 21: 1-18
5. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18: 4047-4054
6. Chehab NH, Malikzay A, Appel M, Halazonetis TD (2000) Chk2/hCdsl functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14: 289-300
7. Easton DF (1999) How many more breast cancer predisposition genes are there. Breast Cancer Res 1: 14-17
8. Ganguly A, Rock MJ, Prockcop DJ (1993) Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and PCR fragments: Evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad USA 90: 10325-10329
9. Hogervorst F, Cornelis R, Bout M, Van Vliet M, Oosterwijk J, Olmer R, Bakker B, Klijn J, Vasen H, Miejers-Heijboer H, Menko F, Cornelisse C, Den Dunnen J, Devilee P, Van Ommen G-J (1995) Rapid detection of BRCA1 mutations by the Protein Truncation Test. Nat Genet 10: 208-212
10. Lee JS, Collins KM, Brown AI, Lee CH, Chung JH (2000) hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404: 201-204
11. Lee CH, Chung JH (2001) The hCds1 (CHK2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem 4: 30537-30541
12. Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893-1897
13. Meijers-Heijboer H, Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, Veghel-Plandsoen M, Elstrodt F, Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton DF, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang H, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber BL, Rahman N, Stratton MR (2002) Low penetrance familial breast cancer susceptibility due to CHK2 1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nature Genetics 31: 55-59
14. Sodha N, Houlston RS, Willaims R, Yuille MA, Mangion J, Eeles RA (2002) A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mutat 19: 173-177
15. Sullivan A, Yuille MA, Repellin C, Reddy A, Reelfs O, Bell A, Dunne B, Gusterson BA, Osin P, Farrell PJ, Yulug I, Evans A, Ozcelik T, Gasco M, Crook T (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21: 1316-1324